Linezolid (PNU-100766) versus vancomycin in the treatment of hospitalized patients with nosocomial pneumonia: A randomized, double-blind, multicenter study

E. Rubinstein; S. K. Cammarata; T. H. Oliphant; R. G. Wunderink; J. Labrooy; J. L. Moran; B. Richards; D. Grimard; S. J. Landis; C. Rotstein; E. Chavez; R. Northland; V. Triantafilo; P. Vasquez; V. Kolek; M. Kucera; P. Reiterer; I. Weidenhoffer; C. Andrews; I. McLaren; M. Street; T. Ali-Malkkilä; J. Heikkinen; P. Kairi; M. Valtonen; B. Georges; L. Holzapfel; A. Leon; C. D. Martin; P. Maurette; J. F. Muir; M. Ossart; B. Veber; J. Lukacs; G. Nagy; Z. Rott; R. Raz; K. Riesenberg; A. Yinnon; M. Molinari; G. Castro; G. Fabian; M. Gaca; L. Krawczyk; J. Malolepszy; R. Szulc; L. Wolowicka; A. G. Chuchalin; T. Fedorova; I. M. Kakhnovskii; V. G. Novozhenov; A. I. Sinopalnikov; J. G. Kilian; W. L. Michell; A. W. Sturm; J. Viljoen; R. Wood; J. M. Pueyo; M. Soler-Obradors; I. M. Baird; M. C. Birmingham; H. S. Bjerke; M. A. Brown; S. J.D. Chow; R. K. Daniels; T. Dickey; A. El-Solh; D. R. Graham; L. R. Grier; J. Hall; M. S. Harrison; M. T. Herbert; R. C. Hyzy; R. J. Kaner; L. S. Larsen; I. Leviton; S. C. Matchett; M. H. Metzler; M. L. Morganroth; A. R. Murthy; P. E. Nolan; N. H. Olson; L. B. Palmer; R. G. Postier; D. P. Remy; G. J. Richmond; M. H. Rosenthal; G. Sanchez; R. B. Schechter; S. J. Simon; T. W. Smith; B. Thompson; B. J. White; B. Hafkin; W. M. Todd; J. Timm; K. Hempsall; L. Schuemann

doi:10.1086/318486

Linezolid (PNU-100766) versus vancomycin in the treatment of hospitalized patients with nosocomial pneumonia: A randomized, double-blind, multicenter study

E. Rubinstein
, S. K. Cammarata
, T. H. Oliphant
, R. G. Wunderink
, J. Labrooy
, J. L. Moran
, B. Richards
, D. Grimard
, S. J. Landis
, C. Rotstein
, E. Chavez
, R. Northland
, V. Triantafilo
, P. Vasquez
, V. Kolek
, M. Kucera
, P. Reiterer
, I. Weidenhoffer
, C. Andrews
, I. McLaren

M. Street, T. Ali-Malkkilä, J. Heikkinen, P. Kairi, M. Valtonen, B. Georges, L. Holzapfel, A. Leon, C. D. Martin, P. Maurette, J. F. Muir, M. Ossart, B. Veber, J. Lukacs, G. Nagy, Z. Rott, R. Raz, K. Riesenberg, A. Yinnon, M. Molinari, G. Castro, G. Fabian, M. Gaca, L. Krawczyk, J. Malolepszy, R. Szulc, L. Wolowicka, A. G. Chuchalin, T. Fedorova, I. M. Kakhnovskii, V. G. Novozhenov, A. I. Sinopalnikov, J. G. Kilian, W. L. Michell, A. W. Sturm, J. Viljoen, R. Wood, J. M. Pueyo, M. Soler-Obradors, I. M. Baird, M. C. Birmingham, H. S. Bjerke, M. A. Brown, S. J.D. Chow, R. K. Daniels, T. Dickey, A. El-Solh, D. R. Graham, L. R. Grier, J. Hall, M. S. Harrison, M. T. Herbert, R. C. Hyzy, R. J. Kaner, L. S. Larsen, I. Leviton, S. C. Matchett, M. H. Metzler, M. L. Morganroth, A. R. Murthy, P. E. Nolan, N. H. Olson, L. B. Palmer, R. G. Postier, D. P. Remy, G. J. Richmond, M. H. Rosenthal, G. Sanchez, R. B. Schechter, S. J. Simon, T. W. Smith, B. Thompson, B. J. White, B. Hafkin, W. M. Todd, J. Timm, K. Hempsall, L. Schuemann

Research output: Contribution to journal › Article › peer-review

456 Scopus citations

Abstract

Linezolid, the first oxazolidinone, is active against gram-positive bacteria, including multidrug-resistant strains. This multinational, randomized, double-blind, controlled trial compared the efficacy, safety, and tolerability of linezolid with vancomycin in the treatment of nosocomial pneumonia. A total of 203 patients received intravenous linezolid, 600 mg twice daily, plus aztreonam, and 193 patients received vancomycin, 1 g intravenously twice daily, plus aztreonam for 7-21 days. Clinical and microbiological outcomes were evaluated at test of cure 12-28 days after treatment. Clinical cure rates (71 [66.4%] of 107 for linezolid vs. 62 [68.1%] of 91 for vancomycin) and microbiological success rates (36 [67.9%] of 53 vs. 28 [71.8%] of 39, respectively) for evaluable patients were equivalent between treatment groups. Eradication rates of methicillin-resistant Staphylococcus aureus and safety evaluations were similar between treatment groups. Resistance to either treatment was not detected. Linezolid is a well-tolerated, effective treatment for adults with gram-positive nosocomial pneumonia.

Original language	English
Pages (from-to)	402-412
Number of pages	11
Journal	Clinical Infectious Diseases
Volume	32
Issue number	3
DOIs	https://doi.org/10.1086/318486
State	Published - 1 Jan 2001
Externally published	Yes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

ASJC Scopus subject areas

Microbiology (medical)
Infectious Diseases

Access to Document

10.1086/318486

Cite this

Rubinstein, E., Cammarata, S. K., Oliphant, T. H., Wunderink, R. G., Labrooy, J., Moran, J. L., Richards, B., Grimard, D., Landis, S. J., Rotstein, C., Chavez, E., Northland, R., Triantafilo, V., Vasquez, P., Kolek, V., Kucera, M., Reiterer, P., Weidenhoffer, I., Andrews, C., ... Schuemann, L. (2001). Linezolid (PNU-100766) versus vancomycin in the treatment of hospitalized patients with nosocomial pneumonia: A randomized, double-blind, multicenter study. Clinical Infectious Diseases, 32(3), 402-412. https://doi.org/10.1086/318486

@article{6da6f96006074596a02e20a2d39177d0,

title = "Linezolid (PNU-100766) versus vancomycin in the treatment of hospitalized patients with nosocomial pneumonia: A randomized, double-blind, multicenter study",

abstract = "Linezolid, the first oxazolidinone, is active against gram-positive bacteria, including multidrug-resistant strains. This multinational, randomized, double-blind, controlled trial compared the efficacy, safety, and tolerability of linezolid with vancomycin in the treatment of nosocomial pneumonia. A total of 203 patients received intravenous linezolid, 600 mg twice daily, plus aztreonam, and 193 patients received vancomycin, 1 g intravenously twice daily, plus aztreonam for 7-21 days. Clinical and microbiological outcomes were evaluated at test of cure 12-28 days after treatment. Clinical cure rates (71 [66.4\%] of 107 for linezolid vs. 62 [68.1\%] of 91 for vancomycin) and microbiological success rates (36 [67.9\%] of 53 vs. 28 [71.8\%] of 39, respectively) for evaluable patients were equivalent between treatment groups. Eradication rates of methicillin-resistant Staphylococcus aureus and safety evaluations were similar between treatment groups. Resistance to either treatment was not detected. Linezolid is a well-tolerated, effective treatment for adults with gram-positive nosocomial pneumonia.",

author = "E. Rubinstein and Cammarata, \{S. K.\} and Oliphant, \{T. H.\} and Wunderink, \{R. G.\} and J. Labrooy and Moran, \{J. L.\} and B. Richards and D. Grimard and Landis, \{S. J.\} and C. Rotstein and E. Chavez and R. Northland and V. Triantafilo and P. Vasquez and V. Kolek and M. Kucera and P. Reiterer and I. Weidenhoffer and C. Andrews and I. McLaren and M. Street and T. Ali-Malkkil{\"a} and J. Heikkinen and P. Kairi and M. Valtonen and B. Georges and L. Holzapfel and A. Leon and Martin, \{C. D.\} and P. Maurette and Muir, \{J. F.\} and M. Ossart and B. Veber and J. Lukacs and G. Nagy and Z. Rott and R. Raz and K. Riesenberg and A. Yinnon and M. Molinari and G. Castro and G. Fabian and M. Gaca and L. Krawczyk and J. Malolepszy and R. Szulc and L. Wolowicka and Chuchalin, \{A. G.\} and T. Fedorova and Kakhnovskii, \{I. M.\} and Novozhenov, \{V. G.\} and Sinopalnikov, \{A. I.\} and Kilian, \{J. G.\} and Michell, \{W. L.\} and Sturm, \{A. W.\} and J. Viljoen and R. Wood and Pueyo, \{J. M.\} and M. Soler-Obradors and Baird, \{I. M.\} and Birmingham, \{M. C.\} and Bjerke, \{H. S.\} and Brown, \{M. A.\} and Chow, \{S. J.D.\} and Daniels, \{R. K.\} and T. Dickey and A. El-Solh and Graham, \{D. R.\} and Grier, \{L. R.\} and J. Hall and Harrison, \{M. S.\} and Herbert, \{M. T.\} and Hyzy, \{R. C.\} and Kaner, \{R. J.\} and Larsen, \{L. S.\} and I. Leviton and Matchett, \{S. C.\} and Metzler, \{M. H.\} and Morganroth, \{M. L.\} and Murthy, \{A. R.\} and Nolan, \{P. E.\} and Olson, \{N. H.\} and Palmer, \{L. B.\} and Postier, \{R. G.\} and Remy, \{D. P.\} and Richmond, \{G. J.\} and Rosenthal, \{M. H.\} and G. Sanchez and Schechter, \{R. B.\} and Simon, \{S. J.\} and Smith, \{T. W.\} and B. Thompson and White, \{B. J.\} and B. Hafkin and Todd, \{W. M.\} and J. Timm and K. Hempsall and L. Schuemann",

year = "2001",

month = jan,

day = "1",

doi = "10.1086/318486",

language = "English",

volume = "32",

pages = "402--412",

journal = "Clinical Infectious Diseases",

issn = "1058-4838",

publisher = "Oxford University Press",

number = "3",

}

Rubinstein, E, Cammarata, SK, Oliphant, TH, Wunderink, RG, Labrooy, J, Moran, JL, Richards, B, Grimard, D, Landis, SJ, Rotstein, C, Chavez, E, Northland, R, Triantafilo, V, Vasquez, P, Kolek, V, Kucera, M, Reiterer, P, Weidenhoffer, I, Andrews, C, McLaren, I, Street, M, Ali-Malkkilä, T, Heikkinen, J, Kairi, P, Valtonen, M, Georges, B, Holzapfel, L, Leon, A, Martin, CD, Maurette, P, Muir, JF, Ossart, M, Veber, B, Lukacs, J, Nagy, G, Rott, Z, Raz, R, Riesenberg, K, Yinnon, A, Molinari, M, Castro, G, Fabian, G, Gaca, M, Krawczyk, L, Malolepszy, J, Szulc, R, Wolowicka, L, Chuchalin, AG, Fedorova, T, Kakhnovskii, IM, Novozhenov, VG, Sinopalnikov, AI, Kilian, JG, Michell, WL, Sturm, AW, Viljoen, J, Wood, R, Pueyo, JM, Soler-Obradors, M, Baird, IM, Birmingham, MC, Bjerke, HS, Brown, MA, Chow, SJD, Daniels, RK, Dickey, T, El-Solh, A, Graham, DR, Grier, LR, Hall, J, Harrison, MS, Herbert, MT, Hyzy, RC, Kaner, RJ, Larsen, LS, Leviton, I, Matchett, SC, Metzler, MH, Morganroth, ML, Murthy, AR, Nolan, PE, Olson, NH, Palmer, LB, Postier, RG, Remy, DP, Richmond, GJ, Rosenthal, MH, Sanchez, G, Schechter, RB, Simon, SJ, Smith, TW, Thompson, B, White, BJ, Hafkin, B, Todd, WM, Timm, J, Hempsall, K & Schuemann, L 2001, 'Linezolid (PNU-100766) versus vancomycin in the treatment of hospitalized patients with nosocomial pneumonia: A randomized, double-blind, multicenter study', Clinical Infectious Diseases, vol. 32, no. 3, pp. 402-412. https://doi.org/10.1086/318486

TY - JOUR

T1 - Linezolid (PNU-100766) versus vancomycin in the treatment of hospitalized patients with nosocomial pneumonia

T2 - A randomized, double-blind, multicenter study

AU - Rubinstein, E.

AU - Cammarata, S. K.

AU - Oliphant, T. H.

AU - Wunderink, R. G.

AU - Labrooy, J.

AU - Moran, J. L.

AU - Richards, B.

AU - Grimard, D.

AU - Landis, S. J.

AU - Rotstein, C.

AU - Chavez, E.

AU - Northland, R.

AU - Triantafilo, V.

AU - Vasquez, P.

AU - Kolek, V.

AU - Kucera, M.

AU - Reiterer, P.

AU - Weidenhoffer, I.

AU - Andrews, C.

AU - McLaren, I.

AU - Street, M.

AU - Ali-Malkkilä, T.

AU - Heikkinen, J.

AU - Kairi, P.

AU - Valtonen, M.

AU - Georges, B.

AU - Holzapfel, L.

AU - Leon, A.

AU - Martin, C. D.

AU - Maurette, P.

AU - Muir, J. F.

AU - Ossart, M.

AU - Veber, B.

AU - Lukacs, J.

AU - Nagy, G.

AU - Rott, Z.

AU - Raz, R.

AU - Riesenberg, K.

AU - Yinnon, A.

AU - Molinari, M.

AU - Castro, G.

AU - Fabian, G.

AU - Gaca, M.

AU - Krawczyk, L.

AU - Malolepszy, J.

AU - Szulc, R.

AU - Wolowicka, L.

AU - Chuchalin, A. G.

AU - Fedorova, T.

AU - Kakhnovskii, I. M.

AU - Novozhenov, V. G.

AU - Sinopalnikov, A. I.

AU - Kilian, J. G.

AU - Michell, W. L.

AU - Sturm, A. W.

AU - Viljoen, J.

AU - Wood, R.

AU - Pueyo, J. M.

AU - Soler-Obradors, M.

AU - Baird, I. M.

AU - Birmingham, M. C.

AU - Bjerke, H. S.

AU - Brown, M. A.

AU - Chow, S. J.D.

AU - Daniels, R. K.

AU - Dickey, T.

AU - El-Solh, A.

AU - Graham, D. R.

AU - Grier, L. R.

AU - Hall, J.

AU - Harrison, M. S.

AU - Herbert, M. T.

AU - Hyzy, R. C.

AU - Kaner, R. J.

AU - Larsen, L. S.

AU - Leviton, I.

AU - Matchett, S. C.

AU - Metzler, M. H.

AU - Morganroth, M. L.

AU - Murthy, A. R.

AU - Nolan, P. E.

AU - Olson, N. H.

AU - Palmer, L. B.

AU - Postier, R. G.

AU - Remy, D. P.

AU - Richmond, G. J.

AU - Rosenthal, M. H.

AU - Sanchez, G.

AU - Schechter, R. B.

AU - Simon, S. J.

AU - Smith, T. W.

AU - Thompson, B.

AU - White, B. J.

AU - Hafkin, B.

AU - Todd, W. M.

AU - Timm, J.

AU - Hempsall, K.

AU - Schuemann, L.

PY - 2001/1/1

Y1 - 2001/1/1

N2 - Linezolid, the first oxazolidinone, is active against gram-positive bacteria, including multidrug-resistant strains. This multinational, randomized, double-blind, controlled trial compared the efficacy, safety, and tolerability of linezolid with vancomycin in the treatment of nosocomial pneumonia. A total of 203 patients received intravenous linezolid, 600 mg twice daily, plus aztreonam, and 193 patients received vancomycin, 1 g intravenously twice daily, plus aztreonam for 7-21 days. Clinical and microbiological outcomes were evaluated at test of cure 12-28 days after treatment. Clinical cure rates (71 [66.4%] of 107 for linezolid vs. 62 [68.1%] of 91 for vancomycin) and microbiological success rates (36 [67.9%] of 53 vs. 28 [71.8%] of 39, respectively) for evaluable patients were equivalent between treatment groups. Eradication rates of methicillin-resistant Staphylococcus aureus and safety evaluations were similar between treatment groups. Resistance to either treatment was not detected. Linezolid is a well-tolerated, effective treatment for adults with gram-positive nosocomial pneumonia.

AB - Linezolid, the first oxazolidinone, is active against gram-positive bacteria, including multidrug-resistant strains. This multinational, randomized, double-blind, controlled trial compared the efficacy, safety, and tolerability of linezolid with vancomycin in the treatment of nosocomial pneumonia. A total of 203 patients received intravenous linezolid, 600 mg twice daily, plus aztreonam, and 193 patients received vancomycin, 1 g intravenously twice daily, plus aztreonam for 7-21 days. Clinical and microbiological outcomes were evaluated at test of cure 12-28 days after treatment. Clinical cure rates (71 [66.4%] of 107 for linezolid vs. 62 [68.1%] of 91 for vancomycin) and microbiological success rates (36 [67.9%] of 53 vs. 28 [71.8%] of 39, respectively) for evaluable patients were equivalent between treatment groups. Eradication rates of methicillin-resistant Staphylococcus aureus and safety evaluations were similar between treatment groups. Resistance to either treatment was not detected. Linezolid is a well-tolerated, effective treatment for adults with gram-positive nosocomial pneumonia.

UR - https://www.scopus.com/pages/publications/0035112879

U2 - 10.1086/318486

DO - 10.1086/318486

M3 - Article

C2 - 11170948

AN - SCOPUS:0035112879

SN - 1058-4838

VL - 32

SP - 402

EP - 412

JO - Clinical Infectious Diseases

JF - Clinical Infectious Diseases

IS - 3

ER -

Linezolid (PNU-100766) versus vancomycin in the treatment of hospitalized patients with nosocomial pneumonia: A randomized, double-blind, multicenter study

Abstract

UN SDGs

ASJC Scopus subject areas

Access to Document

Fingerprint

Cite this